2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 476

Two-Year Results From The Ample Trial: Low Disease Activity and Association Between Remission and Changes In Physical Function and Radiographic Outcomes With Subcutaneous Abatacept Or Adalimumab
Abstract Number: 631

Type I IFN Regulation Of IL-10 Is Detrimental To Endothelial Cell Differentiation and May Enhance Cardiovascular Risk In Systemic Lupus Erythematosus
Abstract Number: 1576

Type I Interferon-Mediated Skewing Of The Serotonin Synthesis In Systemic Lupus Erythematosus Is Associated To Cardiovascular Disease
Abstract Number: 1615

Type I Interferons As a Serum Biomarker Of Subclinical Atherosclerosis In Pediatric Systemic Lupus Erythematosus Patients
Abstract Number: 1627

Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus
Abstract Number: 2373

UK Clinical Practice Use Of Biologics In Monotherapy For The Treatment Of Patients With Rheumatoid Arthritis
Abstract Number: 233

Ultrasonographic Evaluation Of Patellar Cartilage and Triangular Fibrocartilage In Patients With Familial Benign Hypercalcemia
Abstract Number: 578

Ultrasonographic Findings and Inter-Observer Reliability In Danish Patients With Systemic Lupus Erythematosus – a Comparison With Clinical Examination Of Wrist and Hand Joints
Abstract Number: 2320

Ultrasonographic Monitoring Of Response To Infliximab In Patients With Rheumatoid Arthritis
Abstract Number: 2881

Ultrasonographic Salivary Glands Response To Rituximab In Primary Sjögren Syndrome Patients In the Tolerance and Efficacy Of Rituximab In Primary Sjogren Syndrome Study Is Not Associated With The Anatomopathology Changes
Abstract Number: 1963

Ultrasonography Is Helpful For Optimizing The Diagnosis Of Early Rheumatoid Arthritis
Abstract Number: 626

Ultrasound Assessment Of Both Carotid and Femoral Arteries In Patients With Systemic Lupus Erythematosus Increases Sensitivity For Detecting Asymptomatic Atherosclerosis
Abstract Number: 1944

Ultrasound Characteristics Of Extensor Tendon Abnormalities and Peritendinous Fluid In Rheumatoid Arthritis
Abstract Number: 224

Ultrasound Evaluation Of Joints, Tendons and Subcutaneous Tissue Of Hands In 74 Scleroderma Patients
Abstract Number: 855

Ultrasound Evaluation Of The Greater Trochanter Pain Syndrome: Bursitis Or Tendinopathy?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].